Home・Aandelen Lijst・Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

4.29 6.19

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.03

Max

4.32

Belangrijke statistieken
By Trading Economics
Inkomsten	-21M 41M
Verkoop	59M 107M
K/W Sectorgemiddelde	7.129 68.51
EPS	0.24
Winstmarge	38.282
Werknemers	100
EBITDA	66M 75M

Dividenden
By Acuity
Volgende Winsten	9 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-28M 728M
Vorige openingsprijs	-1.9
Vorige sluitingsprijs	4.29

Nieuwssentiment

By Acuity

50%

128 / 340 Rangschikking in Healthcare

Ironwood Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 aug 2026, 19:36 UTC

Ironwood Pharmaceuticals Inc shares are lower today, with no specific news identified. The stock remains significantly down since Friday's close amid broader market volatility.

7 aug 2026, 19:46 UTC

Ironwood Pharmaceuticals Inc shares are higher during Friday's session, maintaining a position above the 20-day moving average, despite earlier fluctuations.

6 aug 2026, 23:06 UTC

Ironwood Pharmaceuticals shares are higher in after-market hours, reflecting positive movement since Thursday's close. No specific news was identified to explain the price action.

5 aug 2026, 23:02 UTC

Ironwood Pharmaceuticals shares are higher in after-market trading, continuing a notable increase since Wednesday's close, despite no specific news identified.

4 aug 2026, 23:01 UTC

Ironwood Pharmaceuticals Inc. shares are lower in after-market trading, showing routine volatility while remaining above the 20-day moving average. No specific news was identified.

3 aug 2026, 19:26 UTC

Ironwood Pharmaceuticals is trading higher today, continuing a rally since Friday's close, amid broader market gains and falling energy prices.

31 jul 2026, 23:26 UTC

Ironwood Pharmaceuticals Inc shares are trading higher in after-market hours, maintaining upward momentum since Friday's close. No specific news was identified for this movement.

30 jul 2026, 20:51 UTC

Ironwood Pharmaceuticals shares declined in after-market trading, despite broader market gains. The stock remains below its 20-day moving average and near a one-month low.

29 jul 2026, 20:04 UTC

Ironwood Pharmaceuticals Inc shares are trading lower amid broader market dynamics, including rising oil prices due to escalating Middle East tensions.

27 jul 2026, 20:06 UTC

Ironwood Pharmaceuticals shares are higher today, reflecting broader market dynamics, despite earlier declines and a significant drop in oil prices.

24 jul 2026, 23:26 UTC

Ironwood Pharmaceuticals shares gained modestly in after-market trading, following a volatile session amid broader turmoil in the bond market.

20 jul 2026, 18:36 UTC

Ironwood Pharmaceuticals Inc is trading higher, reaching a session peak before settling within its one-month range. No specific news was identified for today's movement.

Peer Vergelijking

Prijswijziging

Ironwood Pharmaceuticals Inc Prognose

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Ironwood Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

128 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.